Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australian Kalydeco decision 'deferred,' patients will fight but need a champion

This article was originally published in Scrip

Executive Summary

Cystic fibrosis patients in Australia have lost round one in their battle to get affordable access to Vertex's Kalydeco, after the government-appointed body in charge of granting treatments for reimbursement deferred making a decision on the drug because it is priced too high. Patients in Australia who are eligible for the drug, which is used to treat CF sufferers with the G551D gene, say they feel they have no one "championing" their fight.

You may also be interested in...



Cystic Fibrosis: Successes, Opportunities And Challenges

What is next for the treatment of cystic fibrosis, a rare disease market that has boomed in recent years on the back of new drug approvals with hefty price tags? Pipelines are full, but securing reimbursement is a challenge.

Experience Counts For VC Success: HealthCap Hits 25 Year Mark

VC Playbook: The fundamentals do not change in life sciences investing – good science, unmet need and social responsibility.

Pharma Outlook 2022: What Next After A Year Of Innovation And Growth?

The biopharma industry broke records again in 2021 with the amount of money raised for drug development. After a year of rapid growth, what will 2022 bring for market dynamics and R&D catalysts in biopharma?

Topics

UsernamePublicRestriction

Register

SC022571

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel